Please assess the completion status of the following clinical trial:

Trial Title: A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 years and older at index date~* Diagnosis of MM~* Measurable disease according to IMWG criteria~* ECOG performance status ≤2~* Refractory to at least 1 proteasome inhibitor, 1 immunomodulatory drug, and 1 anti-CD38 treatment (ie, triple-class refractory \[TCR\])~* At least 1 treatment following their TCR eligibility~Exclusion Criteria:~* Acute plasma cell leukemia~* Amyloidosis~* Smoldering MM~* Stem cell transplant within 12 weeks of index or active graft versus host disease (GVHD)~* Active malignancy within 3 years before index, except for basal cell or squamous cell skin cancer or carcinoma in situ~* Administration with an investigational drug within 30 days prior to index

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Elranatamab (Type: None): Patients treated with elranatamab from the MagnetisMM-3 trial
- Standard of care (Type: None): Patients treated with standard-of-care therapies from real-world data sources

Based on this trial design, predict the completion outcome and termination type (if applicable).